Lipoxen Share Discussion Threads

[123asd] 17/11/2010 12:12

Baxter still to be tapped for, what is it, $72m, provided they're happy with results? Also, Company has been trading cash positive these past three months...

[gharri] 17/11/2010 11:46

Expenditure of roughly £3.5 million per anum. 0.9 million cash balance as of june 2010 The 2.0 million from Baxter has helped ease the pressure of costs incured from the clinical trials of LPX. Walbrook brought on board preceding another fund raising to carry the company through 2011. ?.
Cheers.

[123asd] 17/11/2010 11:27

rkhl - both, I think; there is plenty of forthcoming news, and the engagement of a PR firm implies the Company wants to optimise its management.

[rkhl] 17/11/2010 11:02

Looks like we may get a decent up tick to 8.5 in a bit if this buying continues. Good news imminent or does the market like the PR RNS ?

[123asd] 17/11/2010 10:45

Looks like there's an overhang to clear - perhaps someone who took some of the placing at 7p taking some profit. Actual bid/offer at present is around 7.985/8.25. I do get the feeling of upward pressure building though; apart from the 200k mid (I presume a sell), ALL trades so far today have been buys.

Correction: I'm now being quoted 8.126 sell, phone only to buy.

[rkhl] 17/11/2010 10:34

Share price seems rather stuck to 8p, does anyone have L2.

[rkhl] 17/11/2010 09:50

As Scott stated he feels that Lipoxen is seriously undervalued. With probably positive news on the EPO P2 about to be announced I guess they are looking to push for a serious valuation of LPX which is why they have appointed Walbrook PR, all in my opinion so do your own research.

[123asd] 17/11/2010 00:42

As stated, Q4, but according to posters on other threads, could be imminent...

[r0cksteady] 17/11/2010 00:25

When is approximate date of EPO announcement?

[buywell2] 06/11/2010 15:24

To be fair the Directors recently have been buyers of their own stock, one would imagine that they will try to get the best price for them if taken over

The other BIG investor/partners ie the indian and russian partners hold over 50% of shares roughly spit 50/50% and Baxter is building up a position.

So quite a bit of diverse interest which should I reckon ensure fair play

[123asd] 04/11/2010 16:31

alimo - the answer is, they can't - retail shareholders are regularly screwed out of what they feel to be their legitimate rewards for risks taken on the AIM market. To some extent this can be due to unforeseen circumstances, but IMO it generally happens because the interests of the BoD and those of institutional investors take precedence over those of us minnows. Despite the cliched rhetoric, rare is the company on AIM that does actually look after the interests of small shareholders.

[rkhl] 04/11/2010 16:21

I am surprised Baxter haven't already bought the company.

[alimo] 04/11/2010 16:03

Let's face it most of LPX is totally under valued. This went up to 50p a few years ago, and we are 3 years further on with our IP developments. Any ideas just how much per share has been spent on all our R&D and admin costs? If someone comes in with an offer of 20p how does that compensate all those who have stumped up for all these costs. Will the directors protect them, or just fill their pockets?

How can long holders protect themselves against being taken out toooo soooon.

[buywell2] 04/11/2010 09:50

A nice little lift yesterday and another lift today .... expectation of good news from the Indian trials looks to be starting to build some momentum

Sales expectations of EPO in India and the deal struck with SIL is reckoned to be worth circa 10p a share

Which means not only is the share trading at a discount to this deal , and the 1.5m cash it has in the bank, but ......

Signing up a western partner should double that methinks again on EPO alone

That values the Baxter deal at nothing

That value the influenza developments at nothing

Sulixen at nothing

SiRNA forthcoming deal at nothing

And all of the other early stage candidates at nothing

[123asd] 04/11/2010 09:08

Plenty of other news forthcoming too, I believe...

[rkhl] 04/11/2010 08:55

People taking their positions for the EPO P2 boost by the looks of it.

[buywell2] 02/11/2010 07:29

I think the big seller of late has left the building

All we need now is the good news from India and an assault on 15p can begin

[buywell2] 01/11/2010 16:52

Yes I guess they have , I would suspect there could well be several western pharma's who could be potential partners of Lipoxen , waiting in the wings to see how they turn out.

Wouldn't it be nice if there was an auction to get chosen .......

Nice little tick up today

[123asd] 28/10/2010 08:04

buywell - in other words, these P-II EPO results are potentially going to put the Company to a new level.

[buywell2] 28/10/2010 07:09

Currently Partnered with SIIL – Additional European and US Partners to Follow
Over December 2004-September 2005 Lipoxen entered in co-development deals with SIIL, whereby ErepoXen was licensed on a worldwide basis to the Indian company.

Under the deal, royalties will be shared between the two companies should SIIL successfully sublicense ErepoXen to the developed world, and Lipoxen will receive royalties equivalent to 5% of direct sales by SIIL (i.e. in India or SE Asia), or royalties equivalent to 2.5% should SIIL market the product through a third party (i.e. UNICEF or the WHO).

Assuming development remains on track, we would expect there to be enough clinical data generated for Lipoxen and SIIL to indentify a European and US partner for ErepoXen by the end of 2010.

Accounting for Phase-II/III US and European trials, we would envisage regulatory filing by 2013, and launch by 2014, where we would expect the product to target a $9.6bn market. We assume that an improved extended-release formulation could capture a 10% share of this market within 5 years of launch, equivalent to sales of $1.0bn. Assuming a licensing deal that pays a royalty to SIIL equivalent to 12% of sales, of which half is paid away to Lipoxen, this would equate to revenue to the UK-based company of 52m (US$77m).

However, in India, where SIIL has the opportunity to establish a particularly strong
position in the emerging erythropoietin market, we would expect ErepoXen to take a significantly larger market share. Assuming a 2013 Indian launch, we would anticipate that within five years of launch an improved extended-release formulation of erythropoietin would have the opportunity to capture a 30% share of SIIL's domestic market, equivalent to sales of $41m. Assuming royalties to Lipoxen equivalent to 5% of sales, this would equate to revenue to the UK-based company of £1.4m (US$2.0m).

[buywell2] 27/10/2010 21:54

The chart just might indicate that the seller has departed .... it will be interesting to see if 12p now gets hit on the next lift when the EPO news comes out .... which we know will be before xmas, and also know should be good.

[alimo] 27/10/2010 16:42

I wonder what has changed since 2005 when the hopes for the future took LPX from virtually nothing to 50p in 18 months. Surely what we had then has moved quite far along the R&D paths for several strands of our IP. We need support now to give us a lift to get the 200MA moving back upwards. It would be worth waiting for because when that happens the next move of the 50MA through it will no doubt produce a similar action. There's people about that want our 'stuff' so hold on and increase.

[rkhl] 27/10/2010 15:14

I wonder if a large seller was cleared this morning. Good finds there pegasus and buywell. We'll have our re-rating one day (soon).

[rkhl] 27/10/2010 09:18

As we all now a postive result for EPO P2 could send this share price soaring.